Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (يفتح نافذة جديدة)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Source‎: Ann Intern Med 2008;148(12):939-55.

مفهرسة‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (يفتح نافذة جديدة)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (يفتح نافذة جديدة)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Source‎: Am J Hematol 2000;64(1):26-31.

مفهرسة‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (يفتح نافذة جديدة)

Hydroxyurea for the treatment of sickle cell anemia. (يفتح نافذة جديدة)

Platt OS.

Source‎: N Engl J Med 2008;358(13):1362-9.

مفهرسة‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (يفتح نافذة جديدة)

Clinical effectiveness of decitabine in severe sickle cell disease. (يفتح نافذة جديدة)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Source‎: Br J Haematol 2008;141(1):126-9.

مفهرسة‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (يفتح نافذة جديدة)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (يفتح نافذة جديدة)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Source‎: Blood 2010;115(12):2354-63.

مفهرسة‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (يفتح نافذة جديدة)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (يفتح نافذة جديدة)

Hirst C, Owusu-Ofori S.

Source‎: Cochrane Database Syst Rev 2012;(9):CD003427.

مفهرسة‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (يفتح نافذة جديدة)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (يفتح نافذة جديدة)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Source‎: Lancet Haematol 2021;8(5):e323-33.

مفهرسة‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (يفتح نافذة جديدة)

Sickle cell disease. (يفتح نافذة جديدة)

Meremikwu MM, Okomo U.

Source‎: BMJ Clin Evid 2011;02:2402.

مفهرسة‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (يفتح نافذة جديدة)

A phase 3 trial of l-glutamine in sickle cell disease. (يفتح نافذة جديدة)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Source‎: N Engl J Med 2018;379(3):226-35.

مفهرسة‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (يفتح نافذة جديدة)

Malaria chemoprophylaxis in sickle cell disease. (يفتح نافذة جديدة)

Oniyangi O, Omari AA.

Source‎: Cochrane Database Syst Rev 2006;(4):CD003489.

مفهرسة‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (يفتح نافذة جديدة)